23andMe’s board directors resigned as CEO Anne Wojcicki pushed to take the company private, while concerns remain over its financial struggles, privacy issues, and unresolved lawsuits.
genetic testing
Breaking News
Genetic testing and biotechnology company 23andMe is facing numerous challenges, including more than 30 lawsuits.
Subscribe to VCpost newsletter
Most Popular
- From Fractured to Fluid: Hubpay Builds FinTech Platform for UAE Businesses and Beyond
- Precision Under Pressure: Intubation Science's Innovative Solution for Life-Saving Intubations
- Reperio Health Crushes the Status Quo: The Future of Healthcare Is Finally Here
- Global Stocks Near Record Highs as Fed Cuts Interest Rates
- Huawei's $2,800 Trifold Phone Gains Popularity in China Even Among Apple Loyalists
- Genetic Testing Giant 23andMe Loses Entire Board Over CEO’s Privatization Plans
- Game-Changing Neuroprotection: Astrocyte Pharmaceuticals Breakthrough in Brain Injury Treatment
- Why GasTechno® Could Be the Next Big Thing in Renewable Fuels
